0000876661-23-000191.txt : 20230310
0000876661-23-000191.hdr.sgml : 20230310
20230310131106
ACCESSION NUMBER: 0000876661-23-000191
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20230310
DATE AS OF CHANGE: 20230310
EFFECTIVENESS DATE: 20230310
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Myovant Sciences Ltd.
CENTRAL INDEX KEY: 0001679082
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: CA
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 23722853
BUSINESS ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 207-400-3351
MAIL ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NEW YORK STOCK EXCHANGE LLC
CENTRAL INDEX KEY: 0000876661
IRS NUMBER: 000000000
STATE OF INCORPORATION: NY
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-2060
MAIL ADDRESS:
STREET 1: 11 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NEW YORK STOCK EXCHANGE INC
DATE OF NAME CHANGE: 19910628
25-NSE
1
primary_doc.xml
X0203
0000876661
NEW YORK STOCK EXCHANGE LLC
0001679082
Myovant Sciences Ltd.
001-37929
Suite 1, 3rd Floor St. James's Square
London
SW1Y 4LB
+44 203 318 9709
Common Shares, $0.000017727 par value per share
17 CFR 240.12d2-2(a)(3)
Daniel Contrastano
Manager, Market Watch & Proxy Compliance
2023-03-10
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on March 21, 2023, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on March 10, 2023 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
The merger between Myovant Sciences Ltd. and Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd. became effective on March 10, 2023. Each common share of Myovant Sciences Ltd. was exchanged for USD 27.00 in cash.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading before market open on March 10, 2023.